Similarly, development of host IgG “inhibitors” against exogenous Factor VIII (hemophilia A) or Factor IX (hemophilia B) occurs in around 30% and 5% of hemophilia patients, respectively (43–45). The gene discussed is F9; the disease is hemophilia B.